SearchSearach Website
Close Searach

Search Website

A

Larger Smaller

A

Living Well With Low Vision Sponsored by Prevent Blindness
  • Info & News
  • Clinical Trials
  • Resources
  • Free Books
  • Patients’ Writings
  • About
  • Contact
  • Donate
Skip to content
Skip to content

Living Well With Low Vision

  • Info & News
  • Clinical Trials
  • Resources
  • Free Books
  • Patients’ Writings
  • About
  • Contact
  • Donate

News & Archive Categories

    Category: Therapies, Treatments, and Procedures

    New Drug Therapies Are Easing the Burden of Anti-VEGF Treatments

    Posted on June 15, 2022June 15, 2022 by Dan Roberts
  • June 15, 2022

    New Drug Therapies Are Easing the Burden of Anti-VEGF Treatments

    Treatments for neovascularization in the retina may be reduced to as few as two to four times per year.  New anti-VEGF drug therapies are now available for treatment of macular diseases. Over the past two years the U.S. Food and Drug Administration (FDA) has approved less invasive, less burdensome, and lower cost drugs and procedures. […]

      Also posted in
    • Latest News
    • Therapies, Treatments, and Procedures
  • BYOOVIZ™ Launches in the U.S.

    Posted on June 2, 2022June 8, 2022 by Dan Roberts
  • June 2, 2022

    BYOOVIZ™ Launches in the U.S.

    Biogen Inc. and Samsung Bioepis Co., Ltd. has announced that BYOOVIZ™ (ranibizumab-nuna), a biosimilar of LUCENTIS® (ranibizumab) has been launched in the U.S. and will be commercially available on July 1, 2022. The list price will be $1,130 per injection, which is 40% lower than the current list price of LUCENTIS. The FDA approved BYOOVIZ […]

      Also posted in
    • Latest News
    • Therapies, Treatments, and Procedures
  • Does VUITY™ Treat AMD?

    Posted on March 20, 2022 by Dan Roberts
  • March 20, 2022

    Does VUITY™ Treat AMD?

    A new drug called VUITY™ (pilocarpine hydrochloride ophthalmic solution) has recently gained attention as an eye drop that can improve near (close up) vision in individuals over 40. It does not, however, change the condition of the retina. The drug, made by Allergan, works as advertised, but it should not be expected to treat age-related […]

      Also posted in
    • Latest News
    • Therapies, Treatments, and Procedures
  • Long-awaited Faricimab for wet AMD and DME approved

    Posted on January 31, 2022January 31, 2022 by Dan Roberts
  • January 31, 2022

    Long-awaited Faricimab for wet AMD and DME approved

    The FDA has approved Genentech’s Vabysmo (first announced here as faricimab), the only injectable eye medicine approved simultaneously in the U.S. for wet age-related macular degeneration (AMD) and diabetic macular edema (DME). Vabysmo will be administered using flexible dosing regimens based on patient need. The medication targets and inhibits two disease pathways by neutralizing angiopoietin-2 […]

      Also posted in
    • Latest News
    • Research and Developments
    • Therapies, Treatments, and Procedures
  • FDA Approves First Biosimilar Drug for Treatment of Wet AMD

    Posted on November 29, 2021November 29, 2021 by Dan Roberts
  • November 29, 2021

    FDA Approves First Biosimilar Drug for Treatment of Wet AMD

    The U.S. Food and Drug Administration (FDA) has approved Byooviz (ranibizumab-nuna) as the first biosimilar to Lucentis (ranibizumab injection) for the treatment of wet AMD. Byooviz is also approved to treat macular edema and myopic choroidal neovascularization, a vision-threatening complication of myopia (nearsightedness). The drug is administered by intravitreal injection (delivered into the vitreous humor […]

      Also posted in
    • Latest News
    • Therapies, Treatments, and Procedures
  • 1
  • 2
  • 3
  • …
  • 14
  • Next Page »
Some Like it Neat, by Alex Vasquez
© All Rights Reserved
Footer Content Right

Receive News and Updates


 

We look to your generosity to support Prevent Blindness and keep our resources up to date.

Donate Now
  • Facebook
  • Twitter
Privacy Policy
Prevent Blindness

© 2018 Prevent Blindness. All rights reserved.